Padeliporfin potassium is under clinical development by ImPact Biotech and currently in Phase I for Esophageal Cancer.
MedPAC Tackles Accuracy of Medicare Advantage Network Directories
Inaccuracies in Medicare Advantage (MA) directories listing in-network providers — often criticized as being too “narrow” — and flaws in rules governing them need to